Head and neck cancer: response to p53-based therapeutics.
Limited options are available for patients with advanced stage head and neck cancer. The p53 gene is known as the "guardian of the genome." Mutations of the p53 gene predispose to carcinogenesis. The p53 mutations are common in head and neck cancer. Replacement of p53 gene function in preclinical models demonstrates cancer regression and improved survival. Clinical data with an adenoviral based p53 gene delivery product (Advexin) supports safety and clinical response after direct intratumoral injection. We summarize p53-related therapeutics in this review.
Nemunaitis
Jackie
J
Mary Crowley Cancer Research Centers, Dallas, Texas, USA. jnemunaitis@marycrowley.org
Nemunaitis
John
J
D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D005544:Forecasting; D018014:Gene Transfer Techniques; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D014765:Viral Vaccines / Q000627:therapeutic use*
D014765:Viral Vaccines; C512972:advexin